Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jolanta Skarbaliene

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
European Journal of Pharmacology|September 21, 2017
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetesJolanta Skarbaliene, Kristoffer T Rigbolt, Keld Fosgerau, et al.
BMC Gastroenterology|March 22, 2023
Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in ratsJolanta Skarbaliene, Jesper Mosolff Mathiesen, Bjarne Due Larsen, et al.
Peptides|April 8, 2015
The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF ratsJolanta Skarbaliene, Thomas Secher, Jacob Jelsing, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 25, 2017
Modeling energy intake and body weight effects of a long-acting amylin analogueAnnika Brings, Jens Markus Borghardt, Jolanta Skarbaliene, et al.
Journal of Medicinal Chemistry|January 24, 2025
Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use InjectionBjarne Due Larsen, Jesper Skodborg Villadsen, Jolanta Skarbaliene, et al.
Annals of the New York Academy of Sciences|May 17, 2022
The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowelJohannes Reiner, Johanna Thiery, Jascha Held, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|July 14, 2021
The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male ratsLauren M Stein, Lauren E McGrath, Rinzin Lhamo, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|October 27, 2021
Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowelJohannes Reiner, Peggy Berlin, Jascha Held, et al.
Journal of Medicinal Chemistry|November 11, 2025
Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin AnalogueHenrik Fischer Munch, Rasmus Just, Jesper Mosolff Mathiesen, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
European Journal of Pharmacology|September 21, 2017
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetesJolanta Skarbaliene, Kristoffer T Rigbolt, Keld Fosgerau, et al.
BMC Gastroenterology|March 22, 2023
Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in ratsJolanta Skarbaliene, Jesper Mosolff Mathiesen, Bjarne Due Larsen, et al.
Peptides|April 8, 2015
The anti-diabetic effects of GLP-1-gastrin dual agonist ZP3022 in ZDF ratsJolanta Skarbaliene, Thomas Secher, Jacob Jelsing, et al.
Journal of Pharmacokinetics and Pharmacodynamics|November 25, 2017
Modeling energy intake and body weight effects of a long-acting amylin analogueAnnika Brings, Jens Markus Borghardt, Jolanta Skarbaliene, et al.
Journal of Medicinal Chemistry|January 24, 2025
Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use InjectionBjarne Due Larsen, Jesper Skodborg Villadsen, Jolanta Skarbaliene, et al.
Annals of the New York Academy of Sciences|May 17, 2022
The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowelJohannes Reiner, Johanna Thiery, Jascha Held, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology|July 14, 2021
The long-acting amylin/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male ratsLauren M Stein, Lauren E McGrath, Rinzin Lhamo, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|October 27, 2021
Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowelJohannes Reiner, Peggy Berlin, Jascha Held, et al.
Journal of Medicinal Chemistry|November 11, 2025
Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin AnalogueHenrik Fischer Munch, Rasmus Just, Jesper Mosolff Mathiesen, et al.
Pageof 1